Rxivist logo

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement

By Jinkai Zang, Chenjian Gu, Bingjie Zhou, Chao Zhang, Yong Yang, Shiqi Xu, Xueyang Zhang, Yu Zhou, Lulu Bai, Yang Wu, Zhiping Sun, Rong Zhang, Qiang Deng, Zhenghong Yuan, Hong Tang, Di Qu, Dimitri Lavillette, Youhua Xie, Zhong Huang

Posted 21 May 2020
bioRxiv DOI: 10.1101/2020.05.21.107565 (published DOI: 10.1038/s41421-020-00199-1)

Recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic. Currently, there is no vaccine available for preventing SARS-CoV-2 infection. Like closely related severe acute respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2 also uses its receptor-binding domain (RBD) on the spike (S) protein to engage the host receptor, human angiotensin-converting enzyme 2 (ACE2), facilitating subsequent viral entry. Here we report the immunogenicity and vaccine potential of SARS-CoV-2 RBD (SARS2-RBD)-based recombinant proteins. Immunization with SARS2-RBD recombinant proteins potently induced a multi-functional antibody response in mice. The resulting antisera could efficiently block the interaction between SARS2-RBD and ACE2, inhibit S-mediated cell-cell fusion, and neutralize both SARS-CoV-2 pseudovirus entry and authentic SARS-CoV-2 infection. In addition, the anti-RBD sera also exhibited cross binding, ACE2-blockade, and neutralization effects towards SARS-CoV. More importantly, we found that the anti-RBD sera did not promote antibody-dependent enhancement of either SARS-CoV-2 pseudovirus entry or authentic virus infection of Fc receptor-bearing cells. These findings provide a solid foundation for developing RBD-based subunit vaccines for SARS-CoV2. ### Competing Interest Statement The authors have declared no competing interest.

Download data

  • Downloaded 1,639 times
  • Download rankings, all-time:
    • Site-wide: 11,928
    • In microbiology: 694
  • Year to date:
    • Site-wide: 43,010
  • Since beginning of last month:
    • Site-wide: 123,081

Altmetric data


Downloads over time

Distribution of downloads per paper, site-wide


PanLingua

News